S0463 Economic Costs Associated With Reduction in Work Productivity Loss for Ulcerative Colitis Patients Receiving Ustekinumab Using Results From the UNIFI Clinical Trial
Notice bibliographique
Résumé
INTRODUCTION: The economic burden associated with work productivity loss is substantial in patients with ulcerative colitis (UC). The objective of this study was to determine the indirect costs in US dollars associated with changes in work productivity loss (WPL) for UC patients treated with ustekinumab (UST) over a year. METHODS: The Work Productivity and Activity Impairment (WPAI) questionnaire completed by patients in the UNIFI trial was used to assess the average percentage of work time missed (absenteeism) and impairment while at work (presenteeism) due to UC. Absenteeism costs per year were calculated as the product of an annual salary and percentage of work time missed, whereas presenteeism costs were calculated as the product of an annual salary, work time not missed and percentage of productivity impairment. The total cost per patient associated with WPL (absenteeism + presenteeism) was assessed at baseline and after 1 year of treatment with ustekinumab using an annual salary of $54,906, as reported by the Bureau of Labor Statistics and the Census Bureau in 2018. RESULTS: The analysis included 206 UC patients from the UNIFI trial treated with UST 6 mg/kg at induction followed by 90mg taken every 8 or 12 weeks at maintenance (UST 6-UST 90 Q8W/Q12W). Of these, 137 were treated with UST 6-UST 90 Q8W. The average total costs for a UC patient at baseline by arm were $30,716 (UST 6-UST 90 Q8W/Q12W) and $30,697 (UST 6-UST 90 SC Q8W). The average absenteeism, presenteeism and total WPL costs at baseline and week 52 are reported in Figure 1. Treatment with UST 6-UST 90 Q8W/Q12W over 1 year resulted in an estimated reduction of $17,314 in WPL costs per patient (absenteeism: $6,040; presenteeism: $11,274). A similar reduction was estimated for UST 6-UST 90 Q8W treated patients (total per patient: $15,673; absenteeism: $4,887; presenteeism: $10,786). Presenteeism accounted for 65% and 69% of the total WPL costs reduction in patients receiving UST 6-UST 90 Q8W/Q12W and UST 6-UST 90 Q8W, respectively. CONCLUSION: UC patients treated with ustekinumab over a year experienced a reduced absenteeism and impairment while at work, which was associated with savings in WPL costs. The estimated cost reductions after 1 year of treatment with ustekinumab were over $15,000 per patient for the treatment groups assessed. The largest cost reductions were found in presenteeism compared to absenteeism.Figure 1.: Absenteeism, presenteeism and total WPL costs in USD estimated at baseline and week 52 for patients who received ustekinumab.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,005 | 0,008 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,000 |
| Méta-épidémiologie (sens large) | 0,002 | 0,004 |
| Bibliométrie | 0,001 | 0,002 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,002 | 0,001 |
| Science ouverte | 0,001 | 0,000 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,009 | 0,001 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».